Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $18 to $16.
Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $18 to $16.